Artificial Intelligence for better antibody drugs: ready for...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.

5th Annual Targeted Protein Degradation Summit

The 5th Annual Targeted Protein Degradation Summit returns to Boston as the most comprehensive, definitive event of the year, uniting 700+ large pharma, innovative biotech and world-renowne

9th Annual Neurodegenerative Drug Development Summit